Immuron reports continued global sales growth for Travelan
Immuron (ASX:IMC), an Australian-based biopharmaceutical company, has announced continued unaudited sales growth for Travelan, its over-the-counter immune supplement targeting pathogenic bacteria in the gastrointestinal tract.









-6-640x360.png&w=3840&q=75)

